Ligand Pharm
(LGND)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 629,302 | 143,321 | 12,556 | -1,636 | 227,444 |
| Depreciation Amortization | 63,445 | 53,220 | 23,252 | 22,563 | 12,901 |
| Income taxes - deferred | 74,829 | 29,739 | 44,518 | 10,697 | -192,132 |
| Accounts receivable | 25,463 | -29,544 | -8,358 | -8,525 | 6,489 |
| Other Working Capital | -7,628 | -37,476 | -11,374 | -12,705 | 821 |
| Other Operating Activity | -814,747 | 34,799 | 27,976 | 50,339 | -13,796 |
| Operating Cash Flow | $-29,336 | $194,059 | $88,570 | $60,733 | $41,727 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -325,817 | -409,440 | -57,624 | -20,968 | -92,752 |
| PPE Investments | -2,553 | -887 | -2,156 | -1,850 | -93 |
| Net Acquisitions | 800,957 | -5,856 | -26,653 | -93,202 | -9,247 |
| Purchase Of Investment | -1,000 | N/A | N/A | -1,000 | N/A |
| Purchase Sale Intangibles | N/A | -10,000 | 7,054 | -17,695 | -4,030 |
| Other Investing Activity | -4,669 | -7,086 | 7,254 | -17,395 | -10,770 |
| Investing Cash Flow | $466,918 | $-423,269 | $-79,179 | $-134,415 | $-112,862 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 12,401 | 1,189,559 | N/A | N/A | N/A |
| Debt Repayment | -39,724 | -657,255 | N/A | N/A | N/A |
| Common Stock Issued | 2,997 | 110,183 | 4,517 | 6,415 | 8,849 |
| Common Stock Repurchased | -453,428 | -152,962 | -1,966 | -3,901 | -489 |
| Other Financing Activity | -7,418 | -160,940 | -10,074 | -7,508 | 0 |
| Financing Cash Flow | $-485,172 | $328,585 | $-7,523 | $-4,994 | $8,360 |
| Exchange Rate Effect | 83 | -215 | N/A | N/A | N/A |
| Beginning Cash Position | 119,780 | 20,620 | 18,752 | 97,428 | 160,203 |
| End Cash Position | 72,273 | 119,780 | 20,620 | 18,752 | 97,428 |
| Net Cash Flow | $-47,507 | $99,160 | $1,868 | $-78,676 | $-62,775 |
| Free Cash Flow | |||||
| Operating Cash Flow | -29,336 | 194,059 | 88,570 | 60,733 | 41,727 |
| Capital Expenditure | -2,553 | -887 | -2,156 | -1,850 | -93 |
| Free Cash Flow | -31,889 | 193,172 | 86,414 | 58,883 | 41,634 |